These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients. Serinet MO; Jacquemin E; Habes D; Debray D; Fabre M; Bernard O J Pediatr Gastroenterol Nutr; 2002 Apr; 34(4):389-93. PubMed ID: 11930095 [TBL] [Abstract][Full Text] [Related]
3. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S; Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985 [TBL] [Abstract][Full Text] [Related]
6. Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Hänel M; Fiedler F; Thorns C Onkologie; 2001 Oct; 24(5):491-4. PubMed ID: 11694778 [TBL] [Abstract][Full Text] [Related]
7. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Verschuuren EA; Stevens SJ; van Imhoff GW; Middeldorp JM; de Boer C; Koëter G; The TH; van Der Bij W Transplantation; 2002 Jan; 73(1):100-4. PubMed ID: 11792987 [TBL] [Abstract][Full Text] [Related]
8. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases]. Chen DB; Wang Y; Song QJ; Shen DH Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829 [TBL] [Abstract][Full Text] [Related]
9. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation. Luo XY; Mo XD; Xu LP; Zhang XH; Wang Y; Liu KY; Chang YJ; Zhao XY; Huang XJ Ann Hematol; 2020 Nov; 99(11):2649-2657. PubMed ID: 32206854 [TBL] [Abstract][Full Text] [Related]
10. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder. Czyzewski K; Styczynski J; Krenska A; Debski R; Zajac-Spychala O; Wachowiak J; Wysocki M Leuk Lymphoma; 2013 Mar; 54(3):503-6. PubMed ID: 22873830 [TBL] [Abstract][Full Text] [Related]
11. Lymphocyte data in Epstein-Barr-virus induced post-transplant lymphoproliferative disorder treated by rituximab. Entz-Werle N; Cojean N; Barats A; Eyer D; Munzer M; Uring-Lambert B; Falkenrodt A; Babin A; Lutz P Pediatr Transplant; 2003 Aug; 7(4):277-81. PubMed ID: 12890005 [TBL] [Abstract][Full Text] [Related]
12. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation. Yedibela S; Reck T; Niedobitek G; Gramatzki M; Repp R; Hohenberger W; Ott R Transpl Int; 2003 Mar; 16(3):197-201. PubMed ID: 12664216 [TBL] [Abstract][Full Text] [Related]
13. The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis. Yamamoto N; Nishimura N; Takeuchi M; Ito T; Yokozaki H; Hirase S; Kubokawa I; Mori T; Yanai T; Hayakawa A; Takeshima Y; Nishio H; Matsuo M; Imadome K; Iijima K Eur J Pediatr; 2014 Dec; 173(12):1615-8. PubMed ID: 24169729 [TBL] [Abstract][Full Text] [Related]
14. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients. Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845 [TBL] [Abstract][Full Text] [Related]
15. Post-transplant lymphoproliferative disorder--case reports of three children with kidney transplant. Spasojević-Dimitrijeva B; Peco-Antić A; Paripović D; Kruscić D; Krstić Z; Cupić M; Cvetković M; Milosevski-Lomić G; Kostić M Srp Arh Celok Lek; 2014; 142(1-2):83-8. PubMed ID: 24684038 [TBL] [Abstract][Full Text] [Related]
16. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791 [TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab. Garceau P; Couture C; Cantin B; Bernier V; Sénéchal M J Heart Lung Transplant; 2008 Aug; 27(8):928-31. PubMed ID: 18656811 [TBL] [Abstract][Full Text] [Related]
18. Treatment of Epstein-Barr virus--associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review. Zhu K; Chen J; Chen S Hematology; 2005 Oct; 10(5):365-70. PubMed ID: 16273722 [TBL] [Abstract][Full Text] [Related]
19. EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. Fox CP; Burns D; Parker AN; Peggs KS; Harvey CM; Natarajan S; Marks DI; Jackson B; Chakupurakal G; Dennis M; Lim Z; Cook G; Carpenter B; Pettitt AR; Mathew S; Connelly-Smith L; Yin JA; Viskaduraki M; Chakraverty R; Orchard K; Shaw BE; Byrne JL; Brookes C; Craddock CF; Chaganti S Bone Marrow Transplant; 2014 Feb; 49(2):280-6. PubMed ID: 24212561 [TBL] [Abstract][Full Text] [Related]
20. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ; Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]